Genmab (Otc) ((GMAB)), Biontech Se Sponsored Adr ((BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genmab and BioNTech SE are conducting a Phase 1 clinical study titled A Phase 1 Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GEN1042 Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Japanese Subjects With Malignant Solid Tumors. The study aims to assess the safety and tolerability of GEN1042, both as a standalone treatment and in combination with other drugs, in Japanese patients with malignant solid tumors.
The study tests GEN1042, a biological treatment administered intravenously, alone and in combination with Pembrolizumab and various chemotherapies. These interventions target head and neck squamous cell carcinoma (HNSCC) and non-small-cell lung cancer (NSCLC).
This interventional study is non-randomized and follows a sequential intervention model without masking, focusing on treatment as its primary purpose.
The study began on November 24, 2023, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 4, 2025, indicating ongoing progress.
This study could significantly impact the stock performance of Genmab and BioNTech SE, as successful results may enhance their market position in oncology treatments. Investors should monitor competitor activities and industry trends for a comprehensive market analysis.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.